Trial reportRadiation oncology (London, England)2012
Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial.
Trial report in Radiation oncology (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial Comparing Conventional vs Short-course Reduced Volume Conformal Post-surgery Radiation Treatment in Women With Stage I or II Breast Cancer
Feasibility Study of Accelerated Preoperative Radiotherapy for Early Breast Cancer
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Pooled it
- Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis.BMJ (Clinical research ed.) · 2024Pooled it
- Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer.Scientific reports · 2020Pooled it
- Fraction size in radiation therapy for breast conservation in early breast cancer.The Cochrane database of systematic reviews · 2016Pooled it
- Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials.Breast (Edinburgh, Scotland) · 2022Trial
- Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer.BMC cancer · 2021Trial
- Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Trial
- Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer.Radiation oncology (London, England) · 2020Trial
- Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results.Radiation oncology (London, England) · 2016Trial
- Hypofractionation with simultaneous integrated boost for early breast cancer: results of the German multicenter phase II trial (ARO-2010-01).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2014Trial
- Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial.Journal of cancer research and clinical oncology · 2014Trial
- Breast Cancer Radiotherapy Plan Metrics: A Principal Component Analysis Using the Mean Absolute Dose Deviation.Cureus · 2026Article
- Comparison of Dose-Volume Histograms of Three Whole Breast Radiotherapy Regimes: Conventional, Normal Hypofractionation and FAST-FORWARD Hypofractionation.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Postmastectomy Radiation Therapy: An ASTRO/ASCO/SSO Clinical Practice Guideline.Annals of surgical oncology · 2025Article
- Ultra-hypofractionated 5-fraction radiation therapy for early breast cancer into whole breast and regional nodes: experience in a tertiary hospital.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Observational
- Clinical comparison of simultaneous integrated and sequential boost IMRT of tumor bed after breast conserving surgery.African health sciences · 2025Article
- Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast-Conserving Surgery.Cancer medicine · 2025Article
- Sequential or simultaneous-integrated boost in early-stage breast cancer patients: trade-offs between skin toxicity and risk of compromised coverage.Radiation oncology (London, England) · 2025Article
- Oncoplastic breast surgery - a pictorial classification system for surgeons and radiation oncologists (OPSURGE).ANZ journal of surgery · 2024Article
- Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer.Clinical and translational radiation oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTomoBreast is a unicenter, non-blinded randomized trial comparing conventional radiotherapy (CR) vs. hypofractionated Tomotherapy (TT) for post-operative treatment of breast cancer. The purpose of the trial is to compare whether TT can reduce heart and pulmonary toxicity. We evaluate early toxicities.
methodsThe trial started inclusion in May 2007 and reached its recruitment in August 2011. Women with stage T1-3N0M0 or T1-2N1M0 breast cancer completely resected by tumorectomy (BCS) or by mastectomy (MA) who consented to participate were randomized, according to a prescribed computer-generated randomization schedule, between control arm of CR 25x2 Gy/5 weeks by tangential fields on breast/chest wall, plus supraclavicular-axillary field if node-positive, and sequential boost 8x2 Gy/2 weeks if BCS (cumulative dose 66 Gy/7 weeks), versus experimental TT arm of 15x2.8 Gy/3 weeks, including nodal areas if node-positive and simultaneous integrated boost of 0.6 Gy if BCS (cumulative dose 51 Gy/3 weeks). Outcomes evaluated were the pulmonary and heart function. Comparison of proportions used one-sided Fisher's exact test.
resultsBy May 2010, 70 patients were randomized and had more than 1 year of follow-up. Out of 69 evaluable cases, 32 were assigned to CR (21 BCS, 11 MA), 37 to TT (20 BCS, 17 MA). Skin toxicity of grade ≥1 at 2 years was 60% in CR, vs. 30% in TT arm. Heart function showed no significant difference for left ventricular ejection fraction at 2 years, CR 4.8% vs. TT 4.6%. Pulmonary function tests at 2 years showed grade ≥1 decline of FEV1 in 21% of CR, vs. 15% of TT and decline of DLco in 29% of CR, vs. 7% of TT (P = 0.05).
conclusionsThere were no unexpected severe toxicities. Short course radiotherapy of the breast with simultaneous integrated boost over 3 weeks proved feasible without excess toxicities. Pulmonary tests showed a slight trend in favor of Tomotherapy, which will need confirmation with longer follow-up of patients.
trial registration[corrected] ClinicalTrials.gov NCT00459628.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.